Chronic Kidney Disease Market Growth Trajectory Through 2024-2033

Spread the love

The Chronic Kidney Disease Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Chronic Kidney Disease Market:

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

According to The Business Research Company’s Chronic Kidney Disease Global Market Report 2024, The chronic kidney disease market size has grown strongly in recent years. It will grow from $65.74 billion in 2023 to $70.2 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to hypertension and diabetes epidemic, aging population, unhealthy lifestyles, healthcare access disparities, medical advances.

The chronic kidney disease market size is expected to see strong growth in the next few years. It will grow to $88.26 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to healthcare policy focus, precision medicine development, rise in obesity rates, growth in chronic diseases, improved healthcare access. Major trends in the forecast period include early screening campaigns, telemedicine and remote monitoring, patient empowerment programs, community-based care initiatives, nutritional therapy integration.

The increasing prevalence of kidney disease is expected to propel the growth of the chronic kidney disease market going forward. Kidney diseases refer to a group of conditions that affect the function and structure of the kidneys. Medication for kidney disease is used to control blood pressure in patients and decrease protein loss to halt the progression of kidney impairment, manage symptoms, and avoid consequences. For instance, in July 2022, according to the Centers for Disease Control and Prevention, a US-based national public health agency, around 15%, or 37 million people in the US, were affected by kidney disease. Therefore, the increasing prevalence of kidney disease is driving the growth of the chronic kidney disease market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=11969&type=smp

The chronic kidney disease market covered in this report is segmented –

1) By Diagnosis: Blood Test, Urine Test, Imaging Test, Kidney Biopsy

2) By Treatment: Drugs, Dialysis, Kidney Transplant, ACE Inhibitors, Blood Test, Other Treatments

3) By Route of Administration: Oral, Intravenous, Subcutaneous

4) By End-User: Hospital And Clinics, Ambulatory Surgery Centers (ASCs), Dialysis Centers, Other End-Users

Product innovations are a key trend gaining popularity in the chronic kidney disease market. Companies operating in the chronic kidney disease market are developing innovative products to sustain their position in the market. For instance, in August 2022, Bayer, a Germany-based biotechnology and pharmaceutical company, launched the innovative medicine Kerendia (finerenone) to slow down the progression of chronic kidney disease in diabetes patients. It is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist and differs from existing treatments. It blocks mineralocorticoid receptor (MR) overactivation, contributing to CKD progression and cardiovascular damage.

The chronic kidney disease market report table of contents includes: